PLUS THERAPEUTICS INC (PSTV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.10+2.65%
Close 2026-08-27 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — reduce net loss from -$3.92 per share in 2026 to -$2.4 per share in 2027: Q2 FY26 EPS -1.31 vs consensus -0.96.
Plus Therapeutics is advancing its cancer treatments with new leadership and strategic deals. The company raised capital through debt issuance to support development. Analysts expect revenue to grow from about $6.3 million in 2026 to $19.1 million in 2027. The company aims to improve its financial health and product pipeline.
The company is still loss-making and faces volatile management. Recent earnings misses and a 48.6% stock drop show risks. Revenue and earnings remain negative with no clear guidance. The turnaround may stall if clinical progress or funding falters.
The market prices in a continued decline in earnings over the next 3 to 5 years and a high risk profile. Our view differs by focusing on potential recovery from current losses and revenue growth, which the market may be underestimating.
Breaks if: inability to raise capital or severe liquidity issues
Breaks if: EPS loss worsens beyond -$3.92 in FY26 or fails to improve toward -$2.4 in FY27
revenue falls below $6.3 million in FY26 or fails to grow toward $19.1 million in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is in a volatile healthcare company that is currently loss-making. The thesis is in a cautious state, reflecting mixed management execution and recent financial results that are below industry peers.
The market currently prices in a low level of fragility, indicating that significant negative events have not yet been reflected in the stock. The valuation appears cheap compared to peers, suggesting that expectations may be lower than for other companies in the sector.
Fundamentals are likely to remain under pressure due to recent weak financial performance and a high probability of missing future earnings expectations. Management is focusing on advancing clinical trials and expanding commercial rollout, but the overall trajectory remains mixed.
The long-term thesis hinges on the ability of management to execute on clinical and commercial priorities while navigating potential earnings misses. Additionally, broader sector performance and economic conditions, such as the jobs report, could significantly impact the company's outlook.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. Recent financial performance remains weak compared to its industry peers. The company has not broken any new ground, but the situation warrants close monitoring.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, PSTV's performance will depend on management's execution and external economic factors. Not investment advice.